2,103 reports of this reaction
2.3% of all AZITHROMYCIN MONOHYDRATE reports
#6 most reported adverse reaction
PNEUMONIA is the #6 most commonly reported adverse reaction for AZITHROMYCIN MONOHYDRATE, manufactured by Aurobindo Pharma Limited. There are 2,103 FDA adverse event reports linking AZITHROMYCIN MONOHYDRATE to PNEUMONIA. This represents approximately 2.3% of all 89,541 adverse event reports for this drug.
Patients taking AZITHROMYCIN MONOHYDRATE who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is a less commonly reported adverse event for AZITHROMYCIN MONOHYDRATE, but still significant enough to appear in the safety profile.
In addition to pneumonia, the following adverse reactions have been reported for AZITHROMYCIN MONOHYDRATE:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 2,103 FDA reports for AZITHROMYCIN MONOHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 2.3% of all adverse event reports for AZITHROMYCIN MONOHYDRATE, making it a notable side effect.
If you experience pneumonia while taking AZITHROMYCIN MONOHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.